Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Detection of T Wave Peak for Serial Comparisons of JTp Interval.

Hnatkova K, Vicente J, Johannesen L, Garnett C, Strauss DG, Stockbridge N, Malik M.

Front Physiol. 2019 Jul 25;10:934. doi: 10.3389/fphys.2019.00934. eCollection 2019.

2.

Design of a "Lean" Case Report Form for Heart Failure Device Development.

Psotka MA, Fiuzat M, Carson PE, Kao DP, Cerkvenik J, Schaber DE, Verta P, Kazmierski RT, Shinnar M, Stockbridge N, Unger EF, Zuckerman B, Butler J, Felker GM, Konstam MA, Lindenfeld J, Solomon SD, Teerlink JR, O'Connor CM, Abraham WT.

JACC Heart Fail. 2019 Aug 2. pii: S2213-1779(19)30542-6. doi: 10.1016/j.jchf.2019.07.001. [Epub ahead of print] Review.

3.

Errors of Fixed QT Heart Rate Corrections Used in the Assessment of Drug-Induced QTc Changes.

Hnatkova K, Vicente J, Johannesen L, Garnett C, Stockbridge N, Malik M.

Front Physiol. 2019 Jun 18;10:635. doi: 10.3389/fphys.2019.00635. eCollection 2019.

4.

Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC.

Eur Heart J. 2019 Aug 14;40(31):2632-2653. doi: 10.1093/eurheartj/ehz372.

5.

Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention.

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC.

Circulation. 2019 Jul 16;140(3):240-261. doi: 10.1161/CIRCULATIONAHA.119.040167. Epub 2019 May 22.

6.

New Strategies for the Conduct of Clinical Trials in Pediatric Pulmonary Arterial Hypertension: Outcome of a Multistakeholder Meeting With Patients, Academia, Industry, and Regulators, Held at the European Medicines Agency on Monday, June 12, 2017.

Ollivier C, Sun H, Amchin W, Beghetti M, Berger RMF, Breitenstein S, Garnett C, Gullberg N, Hassel P, Ivy D, Kawut SM, Klein A, Lesage C, Migdal M, Nije B, Odermarsky M, Strait J, de Graeff PA, Stockbridge N.

J Am Heart Assoc. 2019 May 21;8(10):e011306. doi: 10.1161/JAHA.118.011306. No abstract available.

7.

Correction to: Implications of Individual QT/RR Profiles-Part 1: Inaccuracies and Problems of Population-Specific QT/Heart Rate Corrections.

Malik M, Garnett C, Hnatkova K, Vicente J, Johannesen L, Stockbridge N.

Drug Saf. 2019 Mar;42(3):473. doi: 10.1007/s40264-019-00801-w.

8.

Correction to: FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.

Senatore F, Jagadeesh G, Rose M, Pillai VC, Hariharan S, Liu Q, McDowell TY, Sapru MK, Southworth MR, Stockbridge N.

Am J Cardiovasc Drugs. 2019 Apr;19(2):227. doi: 10.1007/s40256-019-00335-7.

PMID:
30820768
9.

Stroke prevention in atrial fibrillation: Closing the gap.

Pokorney SD, Gersh BJ, Ahmad A, Al-Khatib SM, Blank M, Coylewright M, DiBattiste P, Healey JS, Hedrich O, Hylek EM, Kline-Rogers E, Peterson ED, Mendys P, Mirro MJ, Naccarelli G, Patel P, Ruff CT, Rutman H, Stockbridge N, Temple R, Granger CB.

Am Heart J. 2019 Apr;210:29-38. doi: 10.1016/j.ahj.2018.10.004. Epub 2018 Oct 25. No abstract available.

PMID:
30731371
10.

Correction to: Implications of Individual QT/RR Profiles-Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes.

Malik M, Garnett C, Hnatkova K, Vicente J, Johannesen L, Stockbridge N.

Drug Saf. 2019 Mar;42(3):475. doi: 10.1007/s40264-019-00802-9.

11.

Efficacy and Effectiveness Too Trials: Clinical Trial Designs to Generate Evidence on Efficacy and on Effectiveness in Wide Practice.

Selker HP, Eichler HG, Stockbridge NL, McElwee NE, Dere WH, Cohen T, Erban JK, Seyfert-Margolis VL, Honig PK, Kaitin KI, Oye KA, D'Agostino RB Sr.

Clin Pharmacol Ther. 2019 Apr;105(4):857-866. doi: 10.1002/cpt.1347. Epub 2019 Feb 12.

12.

Clinical trial design and new therapies for pulmonary arterial hypertension.

Sitbon O, Gomberg-Maitland M, Granton J, Lewis MI, Mathai SC, Rainisio M, Stockbridge NL, Wilkins MR, Zamanian RT, Rubin LJ.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801908. doi: 10.1183/13993003.01908-2018. Print 2019 Jan.

13.

Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study.

Vicente J, Zusterzeel R, Johannesen L, Ochoa-Jimenez R, Mason JW, Sanabria C, Kemp S, Sager PT, Patel V, Matta MK, Liu J, Florian J, Garnett C, Stockbridge N, Strauss DG.

Clin Pharmacol Ther. 2019 Apr;105(4):943-953. doi: 10.1002/cpt.1303. Epub 2019 Jan 18.

14.

International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment.

Blinova K, Dang Q, Millard D, Smith G, Pierson J, Guo L, Brock M, Lu HR, Kraushaar U, Zeng H, Shi H, Zhang X, Sawada K, Osada T, Kanda Y, Sekino Y, Pang L, Feaster TK, Kettenhofen R, Stockbridge N, Strauss DG, Gintant G.

Cell Rep. 2018 Sep 25;24(13):3582-3592. doi: 10.1016/j.celrep.2018.08.079.

15.

Implications of Individual QT/RR Profiles-Part 1: Inaccuracies and Problems of Population-Specific QT/Heart Rate Corrections.

Malik M, Garnett C, Hnatkova K, Vicente J, Johannesen L, Stockbridge N.

Drug Saf. 2019 Mar;42(3):401-414. doi: 10.1007/s40264-018-0736-1. Erratum in: Drug Saf. 2019 Mar 9;:.

16.

Implications of Individual QT/RR Profiles-Part 2: Zero QTc/RR Correlations Do Not Prove QTc Correction Accuracy in Studies of QTc Changes.

Malik M, Garnett C, Hnatkova K, Vicente J, Johannesen L, Stockbridge N.

Drug Saf. 2019 Mar;42(3):415-426. doi: 10.1007/s40264-018-0735-2. Erratum in: Drug Saf. 2019 Feb 6;:.

17.

FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.

Senatore F, Jagadeesh G, Rose M, Pillai VC, Hariharan S, Liu Q, McDowell TY, Sapru MK, Southworth MR, Stockbridge N.

Am J Cardiovasc Drugs. 2019 Feb;19(1):11-20. doi: 10.1007/s40256-018-0297-9. Erratum in: Am J Cardiovasc Drugs. 2019 Apr;19(2):227.

PMID:
30144016
18.

Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials.

Parikh KS, Sharma K, Fiuzat M, Surks HK, George JT, Honarpour N, Depre C, Desvigne-Nickens P, Nkulikiyinka R, Lewis GD, Gomberg-Maitland M, O'Connor CM, Stockbridge N, Califf RM, Konstam MA, Januzzi JL Jr, Solomon SD, Borlaug BA, Shah SJ, Redfield MM, Felker GM.

JACC Heart Fail. 2018 Aug;6(8):619-632. doi: 10.1016/j.jchf.2018.06.008. Review.

19.

Assessing Treatment Effects That Capture Disease Burden in Serious Chronic Diseases.

Akacha M, Binkowitz B, Claggett B, Hung HMJ, Mueller-Velten G, Stockbridge N.

Ther Innov Regul Sci. 2019 May;53(3):387-397. doi: 10.1177/2168479018784912. Epub 2018 Jun 28.

PMID:
29954224
20.

Relationship between International Normalized Ratio and Outcomes in Modern Trials with Warfarin Controls.

McDowell TY, Lawrence J, Florian J, Southworth MR, Grant S, Stockbridge N.

Pharmacotherapy. 2018 Sep;38(9):899-906. doi: 10.1002/phar.2161. Epub 2018 Jul 16.

PMID:
29920722
21.

Leveraging electronic health records for clinical research.

Raman SR, Curtis LH, Temple R, Andersson T, Ezekowitz J, Ford I, James S, Marsolo K, Mirhaji P, Rocca M, Rothman RL, Sethuraman B, Stockbridge N, Terry S, Wasserman SM, Peterson ED, Hernandez AF.

Am Heart J. 2018 Aug;202:13-19. doi: 10.1016/j.ahj.2018.04.015. Epub 2018 Apr 30.

PMID:
29802975
22.

Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?

Chan N, Sager PT, Lawrence J, Ortel T, Reilly P, Berkowitz S, Kubitza D, Eikelboom J, Florian J, Stockbridge N, Rose M, Temple R, Seltzer JH.

Am Heart J. 2018 May;199:59-67. doi: 10.1016/j.ahj.2017.10.002. Epub 2017 Oct 10. Review.

PMID:
29754667
23.

Drug-induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy.

Turner JR, Rodriguez I, Mantovani E, Gintant G, Kowey PR, Klotzbaugh RJ, Prasad K, Sager PT, Stockbridge N, Strnadova C; Cardiac Safety Research Consortium.

J Clin Pharmacol. 2018 Apr 19. doi: 10.1002/jcph.1129. [Epub ahead of print] Review.

PMID:
29672845
24.

Importance of QT/RR hysteresis correction in studies of drug-induced QTc interval changes.

Malik M, Garnett C, Hnatkova K, Johannesen L, Vicente J, Stockbridge N.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):491-503. doi: 10.1007/s10928-018-9587-8. Epub 2018 Apr 12.

25.

Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes.

Greene SJ, Vaduganathan M, Khan MS, Bakris GL, Weir MR, Seltzer JH, Sattar N, McGuire DK, Januzzi JL, Stockbridge N, Butler J.

J Am Coll Cardiol. 2018 Mar 27;71(12):1379-1390. doi: 10.1016/j.jacc.2018.01.047. Epub 2018 Mar 10. Review.

26.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Thanh Hai MT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

J Am Coll Cardiol. 2018 Mar 6;71(9):1021-1034. doi: 10.1016/j.jacc.2017.12.048. Review.

27.

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials.

Hicks KA, Mahaffey KW, Mehran R, Nissen SE, Wiviott SD, Dunn B, Solomon SD, Marler JR, Teerlink JR, Farb A, Morrow DA, Targum SL, Sila CA, Hai MTT, Jaff MR, Joffe HV, Cutlip DE, Desai AS, Lewis EF, Gibson CM, Landray MJ, Lincoff AM, White CJ, Brooks SS, Rosenfield K, Domanski MJ, Lansky AJ, McMurray JJV, Tcheng JE, Steinhubl SR, Burton P, Mauri L, O'Connor CM, Pfeffer MA, Hung HMJ, Stockbridge NL, Chaitman BR, Temple RJ; Standardized Data Collection for Cardiovascular Trials Initiative (SCTI).

Circulation. 2018 Feb 27;137(9):961-972. doi: 10.1161/CIRCULATIONAHA.117.033502. Review.

PMID:
29483172
28.

Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank.

Torok RD, Li JS, Kannankeril PJ, Atz AM, Bishai R, Bolotin E, Breitenstein S, Chen C, Diacovo T, Feltes T, Furlong P, Hanna M, Graham EM, Hsu D, Ivy DD, Murphy D, Kammerman LA, Kearns G, Lawrence J, Lebeaut B, Li D, Male C, McCrindle B, Mugnier P, Newburger JW, Pearson GD, Peiris V, Percival L, Pina M, Portman R, Shaddy R, Stockbridge NL, Temple R, Hill KD.

J Am Heart Assoc. 2018 Feb 10;7(4). pii: e007283. doi: 10.1161/JAHA.117.007283. No abstract available.

29.

Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory.

O'Connor CM, Psotka MA, Fiuzat M, Lindenfeld J, Abraham WT, Bristow MR, Canos D, Harrington RA, Hillebrenner M, Jessup M, Malik FI, Solomon SD, Stockbridge N, Tcheng JE, Unger EF, Whellan DJ, Zuckerman B, Califf RM.

J Am Coll Cardiol. 2018 Jan 30;71(4):443-453. doi: 10.1016/j.jacc.2017.11.048. Review.

30.

Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study.

Vicente J, Zusterzeel R, Johannesen L, Mason J, Sager P, Patel V, Matta MK, Li Z, Liu J, Garnett C, Stockbridge N, Zineh I, Strauss DG.

Clin Pharmacol Ther. 2018 Jan;103(1):54-66. doi: 10.1002/cpt.896. Epub 2017 Nov 16. Review.

31.

Past, present, and future of acute heart failure clinical trials-a high-risk population in search of a strategy.

Butler J, Stockbridge N, Gheorghiade M.

Eur J Heart Fail. 2018 May;20(5):839-841. doi: 10.1002/ejhf.987. Epub 2017 Sep 18. Review. No abstract available.

32.

Evaluating the Renal Safety of Investigational New Drugs: Where Should We Be Going?

Stockbridge N, Blank M, Hausner EA, Thompson A.

Clin Pharmacol Ther. 2017 Sep;102(3):387-388. doi: 10.1002/cpt.745. Epub 2017 Jul 21.

PMID:
28731221
33.

The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery.

Gintant G, Fermini B, Stockbridge N, Strauss D.

Cell Stem Cell. 2017 Jul 6;21(1):14-17. doi: 10.1016/j.stem.2017.06.005. Review.

34.

2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Sable CA, Ivy DD, Beekman RH 3rd, Clayton-Jeter HD, Jenkins KJ, Mahle WT, Morrow WR, Murphy MD, Nelson RM, Rosenthal GL, Stockbridge N, Wessel DL.

J Am Coll Cardiol. 2017 Jul 25;70(4):495-503. doi: 10.1016/j.jacc.2017.04.007. Epub 2017 Jun 29. No abstract available. Erratum in: J Am Coll Cardiol. 2017 Sep 5;70(10):1309.

35.

2017 ACC/AAP/AHA Health Policy Statement on Opportunities and Challenges in Pediatric Drug Development: Learning From Sildenafil.

Sable CA, Ivy DD, Beekman RH 3rd, Clayton-Jeter HD, Jenkins KJ, Mahle WT, Morrow WR, Murphy MD, Nelson RM, Rosenthal GL, Stockbridge N, Wessel DL.

Circ Cardiovasc Qual Outcomes. 2017 Jul;10(7). pii: e000026. doi: 10.1161/HCQ.0000000000000026. Review. No abstract available. Erratum in: Circ Cardiovasc Qual Outcomes. 2017 Nov;10(11):e000035.

36.

Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium.

Piccini JP, Clark RL, Kowey PR, Mittal S, Dunnmon P, Stockbridge N, Reiffel JA, Turakhia MP, Ziegler PD, Kleiman RB, Ismat F, Sager P.

Am Heart J. 2017 May;187:156-169. doi: 10.1016/j.ahj.2017.01.012. Epub 2017 Jan 26. Review.

PMID:
28454799
37.

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F.

Eur Heart J. 2019 Mar 14;40(11):880-886. doi: 10.1093/eurheartj/ehx209.

PMID:
28431138
38.

Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report.

Newman JH, Rich S, Abman SH, Alexander JH, Barnard J, Beck GJ, Benza RL, Bull TM, Chan SY, Chun HJ, Doogan D, Dupuis J, Erzurum SC, Frantz RP, Geraci M, Gillies H, Gladwin M, Gray MP, Hemnes AR, Herbst RS, Hernandez AF, Hill NS, Horn EM, Hunter K, Jing ZC, Johns R, Kaul S, Kawut SM, Lahm T, Leopold JA, Lewis GD, Mathai SC, McLaughlin VV, Michelakis ED, Nathan SD, Nichols W, Page G, Rabinovitch M, Rich J, Rischard F, Rounds S, Shah SJ, Tapson VF, Lowy N, Stockbridge N, Weinmann G, Xiao L.

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1661-1670. doi: 10.1164/rccm.201701-0150WS.

39.

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations.

Butler J, Hamo CE, Udelson JE, O'Connor C, Sabbah HN, Metra M, Shah SJ, Kitzman DW, Teerlink JR, Bernstein HS, Brooks G, Depre C, DeSouza MM, Dinh W, Donovan M, Frische-Danielson R, Frost RJ, Garza D, Gohring UM, Hellawell J, Hsia J, Ishihara S, Kay-Mugford P, Koglin J, Kozinn M, Larson CJ, Mayo M, Gan LM, Mugnier P, Mushonga S, Roessig L, Russo C, Salsali A, Satler C, Shi V, Ticho B, van der Laan M, Yancy C, Stockbridge N, Gheorghiade M.

Circ Heart Fail. 2017 Apr;10(4). pii: e003800. doi: 10.1161/CIRCHEARTFAILURE.116.003800.

40.

JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure Prevention.

Fiuzat M, Mayne ST, Hillebrenner M, Stockbridge N, Zuckerman B, Califf RM.

JACC Heart Fail. 2017 Mar;5(3):229-231. doi: 10.1016/j.jchf.2016.12.012. Review. No abstract available.

41.

FDA in the 21st Century: Focus on Tobacco Policies and Heart Failure Prevention.

Fiuzat M, Nordenberg TS, Zeller M, Hillebrenner MG, Stockbridge N, Zuckerman B, Califf RM.

JACC Heart Fail. 2017 Feb;5(2):152-153. doi: 10.1016/j.jchf.2016.11.010. No abstract available.

42.

The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development.

Stockbridge N, Miller K, Amur S, Hillebrenner M, Zuckerman B, Fiuzat M, Califf RM.

JACC Heart Fail. 2017 Jan;5(1):67-70. doi: 10.1016/j.jchf.2016.10.009. Review. No abstract available.

43.

Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.

Huo J, Kamalakar A, Yang X, Word B, Stockbridge N, Lyn-Cook B, Pang L.

Toxicol Sci. 2017 Mar 1;156(1):25-38. doi: 10.1093/toxsci/kfw235.

PMID:
28031415
44.

The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure Devices.

Hillebrenner M, Zuckerman B, Fiuzat M, Stockbridge N, Califf R.

JACC Heart Fail. 2016 Dec;4(12):974-977. doi: 10.1016/j.jchf.2016.09.007. No abstract available.

45.

Food and Drug Administration Analysis of Ticagrelor: Using Data From an Enriched Trial to Evaluate Benefit-Risk Difference in an Unstudied Population.

McDowell TY, Blank M, Lawrence J, Stockbridge N.

Circulation. 2016 Nov 8;134(19):1500-1502. No abstract available.

PMID:
27821420
46.

Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction.

Butler J, Hamo CE, Udelson JE, Pitt B, Yancy C, Shah SJ, Desvigne-Nickens P, Bernstein HS, Clark RL, Depre C, Dinh W, Hamer A, Kay-Mugford P, Kramer F, Lefkowitz M, Lewis K, Maya J, Maybaum S, Patel MJ, Pollack PS, Roessig L, Rotman S, Salsali A, Sims JJ, Senni M, Rosano G, Dunnmon P, Stockbridge N, Anker SD, Zile MR, Gheorghiade M.

Circ Heart Fail. 2016 Nov;9(11). pii: e003358.

PMID:
27756791
47.

Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.

Blinova K, Stohlman J, Vicente J, Chan D, Johannesen L, Hortigon-Vinagre MP, Zamora V, Smith G, Crumb WJ, Pang L, Lyn-Cook B, Ross J, Brock M, Chvatal S, Millard D, Galeotti L, Stockbridge N, Strauss DG.

Toxicol Sci. 2017 Jan;155(1):234-247. doi: 10.1093/toxsci/kfw200. Epub 2016 Oct 3.

48.

Resourcing Drug Development Commensurate With its Public Health Importance: The Road Ahead.

Fiuzat M, Stockbridge N, Califf RM.

JACC Basic Transl Sci. 2016 Aug 29;1(5):309-312. doi: 10.1016/j.jacbts.2016.07.003. eCollection 2016 Aug. No abstract available.

49.

Evolving regulatory paradigm for proarrhythmic risk assessment for new drugs.

Vicente J, Stockbridge N, Strauss DG.

J Electrocardiol. 2016 Nov - Dec;49(6):837-842. doi: 10.1016/j.jelectrocard.2016.07.017. Epub 2016 Jul 28.

PMID:
27524478
50.

Reliable and developmentally appropriate study end points are needed to achieve drug development for treatment of pediatric pulmonary arterial hypertension.

Sun H, Stockbridge N, Ariagno RL, Murphy D, Nelson RM, Rodriguez W.

J Perinatol. 2016 Dec;36(12):1029-1033. doi: 10.1038/jp.2016.103. Epub 2016 Jul 14. Review.

Supplemental Content

Loading ...
Support Center